Stephen F. Betz Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

Stephen F. Betz is Chief Scientific Officer of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 71,358 shares of CRNX, which is worth approximately $3.85 Million. The most recent transaction as insider was on Dec 16, 2024, when has been sold 2,331 shares (Common Stock) at a price of $1.91 per share, resulting in proceeds of $4,452. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 71.4K

4.06% 3M change

13.29% 12M change

Total Value Held $3.85 Million

Stephen F. Betz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 16 2024	BUY Exercise of conversion of derivative security	$4,452 $1.91 p/Share	2,331 Added 3.16%	71,358 Common Stock
Sep 10 2024	SELL Open market or private sale	$53,302 $51.5 p/Share	1,035 Reduced 1.49%	68,576 Common Stock
Aug 26 2024	SELL Open market or private sale	$159,570 $53.19 p/Share	3,000 Reduced 4.13%	69,611 Common Stock
Aug 12 2024	SELL Open market or private sale	$143,040 $47.68 p/Share	3,000 Reduced 3.97%	72,611 Common Stock
Jul 25 2024	SELL Open market or private sale	$160,290 $53.43 p/Share	3,000 Reduced 3.82%	75,611 Common Stock
Jul 10 2024	SELL Open market or private sale	$145,650 $48.55 p/Share	3,000 Reduced 3.68%	78,611 Common Stock
Jun 25 2024	SELL Open market or private sale	$136,110 $45.37 p/Share	3,000 Reduced 3.59%	80,643 Common Stock
Jun 10 2024	SELL Open market or private sale	$131,580 $43.86 p/Share	3,000 Reduced 3.46%	83,643 Common Stock
May 28 2024	SELL Open market or private sale	$142,470 $47.49 p/Share	3,000 Reduced 3.35%	86,643 Common Stock
May 10 2024	SELL Open market or private sale	$148,290 $49.43 p/Share	3,000 Reduced 3.24%	89,643 Common Stock
Mar 18 2024	SELL Payment of exercise price or tax liability	$139,401 $38.14 p/Share	3,655 Reduced 3.8%	92,643 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	23,000 Added 19.28%	96,298 Common Stock
Jan 25 2024	SELL Open market or private sale	$111,780 $37.26 p/Share	3,000 Reduced 3.93%	73,298 Common Stock
Jan 10 2024	SELL Open market or private sale	$112,950 $37.65 p/Share	3,000 Reduced 3.78%	76,298 Common Stock
Dec 26 2023	SELL Open market or private sale	$107,670 $35.89 p/Share	3,000 Reduced 3.65%	79,298 Common Stock
Dec 11 2023	SELL Open market or private sale	$98,609 $32.87 p/Share	3,000 Reduced 3.52%	82,298 Common Stock
Nov 27 2023	SELL Open market or private sale	$95,520 $31.84 p/Share	3,000 Reduced 3.4%	85,298 Common Stock
Mar 16 2023	SELL Payment of exercise price or tax liability	$24,139 $17.12 p/Share	1,410 Reduced 1.6%	86,879 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	23,600 Added 21.09%	88,289 Common Stock
Feb 01 2023	SELL Open market or private sale	$61,238 $19.59 p/Share	3,126 Reduced 4.61%	64,689 Common Stock
Jan 25 2023	SELL Open market or private sale	$175,639 $21.07 p/Share	8,336 Reduced 10.95%	67,815 Common Stock
Jan 17 2023	SELL Open market or private sale	$56,268 $18.0 p/Share	3,126 Reduced 3.94%	76,151 Common Stock
Jan 03 2023	SELL Open market or private sale	$57,362 $18.35 p/Share	3,126 Reduced 3.79%	79,277 Common Stock
Dec 15 2022	SELL Open market or private sale	$50,016 $16.0 p/Share	3,126 Reduced 3.65%	82,403 Common Stock
Dec 01 2022	SELL Open market or private sale	$55,767 $17.84 p/Share	3,126 Reduced 3.55%	84,968 Common Stock

SFB

Stephen F. Betz

Chief Scientific Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Value

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX

Account